Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens

Journal of Acquired Immune Deficiency Syndromes

Volumn 23, Issue 5, 2000, Pages 386-395

  Gifford, Allen L ^a,b,e   Bormann, Jill E ^a,b   Shively, Martha J ^a,c   Wright, Brian C ^a,b   Richman, Douglas D ^a,b   Bozzette, Samuel A ^a,b,d  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN DIEGO STATE UNIVERSITY   (United States)

^d RAND CORPORATION   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti HIV agents; HIV infections; HIV RNA concentration; Patient compliance; Therapy

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SELF REPORT; VIRUS DETECTION;

EID: 0034655019     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200004150-00005     Document Type: Article

References (57)

1. Von Korff M, Gruman J, Schaefer J, Curry SJ, Wagner EH. Collaborative management of chronic illness. Ann Intern Med 1997; 127:1097-1102.
2. Greenfield S, Kaplan SH, Ware JE Jr, Yano EM, Frank HJ. Patients' participation in medical care: effects on blood sugar control and quality of life in diabetes. J Gen Intern Med 1988;3:448-57.
3. Haynes RB, Taylor DW, Sackett DL. Compliance in health care. Baltimore: Johns Hopkins University Press, 1979.
4. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997;102:43-9.
5. DiMatteo MR, DiNicola DD. Achieving patient compliance: the psychology of the medical practitioner's role. New York: Pergamon Press, 1982.
6. Singh N, Berman SM, Swindells S, et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis 1999;29:824-30.
7. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response: California Collaborative Treatment Group. AIDS 1999;13:1099-1107.
8. Paterson DL, Swindels S, Mohr JA, et al. Adherence with protease-inhibitor therapy for human immunodeficiency virus infection. In: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1998. San Diego, California: American Society for Microbiology; 1998:I-172.
9. Kastrissios H, Suárez J-R, Katzenstein D, Girard P, Sheiner LB, Blaschke TF. Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. AIDS 1998;12: 2295-2303.
10. Havlir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team [see comments]. N Engl J Med 1998;339:1261-8.
11. Pialoux G, Raffi F, Brun-Vezinet F, et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team [see comments]. N Engl J Med 1998;339:1269-76.
12. Reijers MH, Weverling GJ, Jurriaans S, et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998;352:185-90.
13. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study [see comments]. JAMA 1998;279:930-7.
14. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998;339:307-11.
15. Shafer RW, Winters MA, Palmer S, Merigan TC. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients [see comments]. Ann Intern Med 1998;128:906-11.
16. Report of the NIH Panel to Define Principles of Therapy of HIV Infection. MMWR Morb Mortal Wkly Rep 1998;47:1-41.
17. Adherence to potent antiretroviral therapy: guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation, December 1, 1998. Available at: http:// hivatis.org/trtgdlns.html
18. Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000;283:381-90.
19. Samuels JE, Hendrix J, Hilton M, Marantz PR, Sloan V, Small CB. Zidovudine therapy in an inner city population. J Acquir Immune Defic Syndr 1990;3:877-83.
20. Morse EV, Simon PM, Coburn M, Hyslop N, Greenspan D, Balson PM. Determinants of subject compliance within an experimental anti-HIV drug protocol. Soc Sci Med 1991;32:1161-7.
21. Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care 1996;8:261-9.
22. Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med 1992;92:495-502.
23. Broers B, Morabia A, Hirschel B. A cohort study of drug users' compliance with zidovudine treatment [see comments]. Arch Intern Med 1994;154:1121-7.
24. Muma RD, Ross MW, Parcel GS, Pollard RB. Zidovudine adherence among individuals with HIV infection. AIDS Care 1995;7: 439-47.
25. Ferrando SJ, Wall TL, Batki SL, Sorensen JL. Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease. Am J Drug Alcohol Abuse 1996;22:475-87.
26. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B. Self-reported adherence to antiretroviral medications among participants in HIV Clinical Trials: The ACTG Adherence Instrument. AIDS Care 2000 (in press).
27. Roca B, Gomez CJ, Arnedo A. Stavudine, lamivudine and indinavir in drug abusing and non-drug abusing HIV-infected patients: adherence, side effects and efficacy. J Infect 1999;39:141-5.
28. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999;13:1763-9.
29. Kalichman SC, Ramachandran B, Catz S. Adherence to combination antiretroviral therapies in HIV patients of low health literacy [see comments]. J Gen Intern Med 1999;14:267-73.
30. Lorig K. Outcome measures for health education and other health care interventions. Thousand Oaks, CA: Sage Publications, 1996.
31. Berry SH, Brown JA, Athey L, et al. HCSUS baseline patient questionnaire documentation [MR-1090-AHCPR]. Santa Monica, CA: RAND, 2000.
32. Johnston J. Econometric methods. New York: McGraw-Hill, 1997.
33. Shumaker SA, Schron EB, Ockene JK, McBee WL. The handbook of health behavior change, 2nd ed. New York: Springer, 1998.
34. Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society - USA Panel [see comments]. JAMA 1998; 279:1984-91.
35. Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral and Pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:117-25.
36. Rudd P, Ahmed S, Zachary V, Barton C, Bonduelle D. Improved compliance measures: applications in an ambulatory hypertensive drug trial. Clin Pharmacol Ther 1990;48:676-85.
37. Urquhart J. Role of patient compliance in clinical pharmacokinetics. A review of recent research. Clin Pharmacokinet 1994;27: 202-15.
38. Straka RJ, Fish JT, Benson SR, Sun JT. Patient self-reporting of compliance does not correspond with electronic monitoring: an evaluation using isosorbide dinitrate as a model drug. Pharmacotherapy 1997;17:126-32.
39. Ickovics RJ, Meisler AW. Adherence in AIDS clinical trials: a framework for clinical research and clinical care. J Clin Epidemiol 1997;50:385-91.
40. Gifford AL, Laurent DD, Gonzalez VM, Chesney MA, Lorig KR. Pilot randomized trial of education to improve self-management skills of men with symptomatic HIV/AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:136-44.
41. Ries AL, Kaplan RM, Limberg TM, Prewitt LM. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995;122:823-32.
42. Clark NM, Janz NK, Dodge JA, Sharpe PA. Self-regulation of health behavior: the "take PRIDE" program. Health Educ Q 1992; 19:341-54.
43. Wenger N, Gifford A, Liu H, et al. Patient characteristics and attitudes associated with antiretroviral adherence. Presented at the 6th Conference on Antiretrovirals and Opportunistic Infections, Chicago, 1999.
44. Kleinman A. The illness narratives: suffering, healing, and the human condition. New York: Basic Books, 1988.
45. Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differences in the use of drug therapy for HIV disease in an urban community [see comments]. N Engl J Med 1994;330:763-8.
46. Wall TL, Sorensen JL, Batki SL, Delucchi KL, London JA, Chesney MA. Adherence to zidovudine (AZT) among HIV-infected methadone patients: a pilot study of supervised therapy and dispensing compared to usual care. Drug Alcohol Depend 1995;37: 261-9.
47. Brown AE, Malone JD, Zhou SY, Lane JR, Hawkes CA. Human immunodeficiency virus RNA levels in US adults: a comparison based upon race and ethnicity. J Infect Dis 1997;176:794-7.
48. Beck AT. Depression: clinical, experimental, and theoretical aspects. New York: Hoeber Medical Division, Harper & Row, 1967.
49. Cohen S, Williamson GM. Perceived stress in a probability sample of the United States. In: Spacapan S, ed. The social psychology of health. The Claremont Symposium on Applied Social Psychology. Newbury Park, CA: Sage Publications, 1988:31-67.
50. Stewart AL, Ware JE. Measuring functioning and well-being: the medical outcomes study approach. Durham: Duke University Press, 1992.
51. Cohen S, Hoberman HM. Positive events and social supports as buffers of life change stress. J Appl Soc Psychol 1983;13:99-125.
52. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care 1991;29:786-98.
53. Wu AW, Hays RD, Kelly S, Malitz F, Bozzette SA. Applications of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS. Qual Life Res 1997;6:531-54.
54. Mathews WC, McCutchan JA, Asch S, et al. National Estimates of HIV-related symptom prevalence: baseline results from the HIV Cost and Services Utilization Study. Med Care 2000 (in press).
55. Whalen CC, Antani M, Carey J, Landefeld CS. An index of symptoms for infection with human immunodeficiency virus: reliability and validity. J Clin Epidemiol 1994;47:537-46.
56. Berry SH, Bozzette SA, Hays RD, Stewart AL, Kanouse DE. Measuring patient-reported health status in advanced HIV disease: HIV-PARSE survey instrument. Santa Monica, CA: RAND, 1994.
57. U.S. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993;269:729-30.